Cooper Companies reported strong financial results for Q3 2024, with revenue increasing 7.8% to $1.0 billion compared to $930.2 million in Q3 2023. Net income rose 22.7% to $104.7 million, with diluted earnings per share of $0.52. The growth was driven by solid performance across both business segments, with CooperVision sales up 7% to $675.6 million and CooperSurgical sales growing 9% to $327.2 million.Operating income increased 27% to $192.5 million, with operating margin expanding to 19% from 16% in the prior year period. CooperVision's growth was led by toric and multifocal lenses, which grew 10% to $326.4 million, while CooperSurgical benefited from strong performance in office and surgical products, which increased 11% to $197.9 million. Both segments saw growth across all major geographic regions despite currency headwinds.The company maintained a strong balance sheet with $109.7 million in cash and entered into a new $2.3 billion revolving credit facility in May 2024. Research and development investments increased 7% to $39 million as the company continued to focus on product innovation. Management remains optimistic about long-term growth prospects in the worldwide contact lens and healthcare markets despite ongoing macroeconomic uncertainties.

Cooper Companies reported strong financial results for Q3 2024, with revenue increasing 7.8% to $1.0 billion compared to $930.2 million in Q3 2023. Net income rose 22.7% to $104.7 million, with diluted earnings per share of $0.52. The growth was driven by solid performance across both business segments, with CooperVision sales up 7% to $675.6 million and CooperSurgical sales growing 9% to $327.2 million.Operating income increased 27% to $192.5 million, with operating margin expanding to 19% from 16% in the prior year period. CooperVision's growth was led by toric and multifocal lenses, which grew 10% to $326.4 million, while CooperSurgical benefited from strong performance in office and surgical products, which increased 11% to $197.9 million. Both segments saw growth across all major geographic regions despite currency headwinds.The company maintained a strong balance sheet with $109.7 million in cash and entered into a new $2.3 billion revolving credit facility in May 2024. Research and development investments increased 7% to $39 million as the company continued to focus on product innovation. Management remains optimistic about long-term growth prospects in the worldwide contact lens and healthcare markets despite ongoing macroeconomic uncertainties.